Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)

Date

12 Dec 2024

Session

Poster Display session

Presenters

Wenhui Yang

Citation

Annals of Oncology (2024) 24 (suppl_1): 1-26. 10.1016/iotech/iotech100745

Authors

W. Yang, C. Zhang, J. Gao, Y. Shi

Author affiliations

  • Shanxi Provincial Cancer Hospital, Taiyuan/CN

Resources

This content is available to ESMO members and event participants.

Abstract 131P

Background

PD-1 inhibitors plus chemotherapy was approved as standard 1L treatment for advanced HER2-negative G/GEJA, but its outcomes remain poor in patients (pts) with low PD-L1 expression. For advanced HER2-positive G/GEJA, integrating immunotherapy with trastuzumab and chemotherapy has shown a significant improvement in progression-free survival (PFS) and overall survival (OS). Cadonilimab, a PD-1/CTLA-4 bispecific antibody, has demonstrated its efficacy and safety in previously untreated advanced G/GEJA pts, even those with PD-L1 CPS<5 in a phase III study. Currently, cadonilimab plus XELOX as 1L treatment for advanced G/GEJA was approved by NMPA. This phase II trial was to assess the efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX in advanced G/GEJA.

Methods

Untreated G/GEJA pts received cadonilimab+SOX (HER2-negative pts) or cadonilimab+trastuzumab+ SOX (HER2-positive pts) for up to 6 cycles, followed by maintenance with S-1+cadonilimab with (HER2-positive pts) or without trastuzumab (HER2-negative pts) until disease progression or intolerable toxicities. The primary endpoint was objective response rate (ORR), and secondary endpoints were disease control rate (DCR), PFS, OS, and safety.

Results

As of September 24, 2024, 19 pts were enrolled, of which 13 (68.4%) were HER2 negative and 6 (31.6%) were HER2 positive. The median age was 62.0 (range: 21-74) and 8 (42.1%) were PD-L1 CPS<5 and HER2 negative. One pt had no post-baseline tumor assessment in HER2-negative pts. Among HER2-positive pts, 6 reached PR, the ORR and DCR were both 100.0%. Of the HER2-negative pts, 6 were PR and 6 exhibited SD, the ORR was 50.0% (6/12) and DCR was 100.0% (12/12). Among HER2-negative pts with PD-L1 CPS<1, the ORR was 57.1% (4/7) and DCR was 100.0% (7/7). Median PFS and OS were not mature. 3 pts (15.0%) developed grade 3 treatment-related adverse events (TRAEs). There were no grade 4/5 TRAEs.

Conclusions

Cadonilimab with or without trastuzumab in combination with SOX showed promising efficacy and tolerable safety as 1L treatment in HER2-positive or HER2-negative advanced G/GEJA, particularly a high ORR in HER2-positive group.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.